PFE Pfizer Inc Price-to-Projected Revenue Ratio

Pfizer Inc. (PFE) leverages its colossal capital to acquire biotech startups and establish monopoly pricing. The forward P/S history on GURU.Markets reflects a turning point driven by generic pressure and patent battles, although a stable brand image continues to support the company. The current 0.60 metric confirms investor expectations for future revenue amid stringent regulatory policies.

pfizer.com - PFE Future Price to Revenue (period 07/04/2022 - 11/13/2026)

Financial and market metric breakdowns for Pfizer Corp (PFE)

- current price and projected stock value:

Stock Price Pfizer|PFE - Analyst Target Range

- market capitalization data:

Market Value Pfizer Corp|PFE - Full Business Value

- book value of equity indicators:

Book Value per Share Pfizer|PFE - Net Asset Value|Market Capitalization to Book Value Ratio pfizer.com|PFE - Company Total Asset Base

- debt burden and liquidity indicators:

- financial results and valuation multiples details:

PFE - Net Financial Result|Expected Profit Pfizer Inc.|PFE - Price to Earnings Multiple|Forward P/E Multiple Pfizer Corporation|PFE - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Pfizer Corp|PFE - Operating income before deduction of amortization|Earnings per share for the last twelve months Pfizer|PFE - Earnings per one share for the last 12 months|Quarterly EPS earnings growth pfizer.com|PFE - Earnings per share trend in current year|Earnings growth forecast for next year Pfizer Inc.

- sales volume and revenue information:

PFE - Company Total Revenue|Company Projected Revenue Pfizer|PFE - Price-to-Sales Ratio|Forward P/S Multiple Pfizer Corp

Initial company analysis:PFE (Pfizer)

To minimize risks when constructing a long-term portfolio, it is critical to align market capitalization with expected sales volumes. In the case of Pfizer Inc. (PFE), the integration of Seagen and the oncology pipeline update must offset the revenue decline from COVID-19 products. By analyzing the future P/S multiple on the GURU.Markets platform, an investor assesses the value of each unit of future revenue, which allows for an objective confirmation of the business's fundamental stability.

Key competitors

Forward P/S Multiple LLY (Eli Lilly)|Projected Price to Revenue AbbVie Inc|AZN - Price-to-Projected Revenue Ratio|Future Price to Revenue NVS|MRK: Forward P/S Multiple|Future Price to Revenue NVO (novonordisk.com)|AMGN (Amgen) - Forward P/S Multiple|Sanofi SA (SNY) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple BMY (BMS)|GSK: Future Price to Revenue|Forward P/S Multiple TAK (Takeda Pharmaceutical)|tevapharm.com (TEVA) - Market Cap to Future Revenue Ratio|RDY - Price-to-Projected Revenue Ratio|Forward Price to Sales VTRS (Viatris Inc)|ROIV (Roivant Sciences Ltd) - Forward Price-to-Revenue Multiple|Zai Lab Corp - Forward Price to Sales|BHC (Bausch Health Companies) - Forward P/S Multiple|cosmosholdingsinc.com (COSM) - Market Cap to Expected Sales Ratio